What These Claims Involve
GLP-1 receptor agonists are prescribed for type 2 diabetes and for weight management. They work partly by slowing gastric emptying, which is central both to how they produce satiety and to the injuries alleged.
Litigation alleges that some patients developed severe and persistent gastrointestinal conditions including gastroparesis, meaning stomach paralysis, intestinal obstruction and severe recurrent vomiting, and that labelling did not adequately convey that risk.
The mechanism and the alleged injury are related
These medicines deliberately slow gastric emptying. The allegation is not that this effect was unknown, but that the severity and persistence of gastrointestinal outcomes in some patients was not adequately conveyed to prescribers.
The Legal Theories
Failure to warn is the principal claim, assessed under the learned intermediary doctrine in most states, so adequacy is judged by what the prescribing physician was told in professional labelling rather than by patient materials.
Design defect claims are pleaded alongside, and preemption is the main defence. For brand-name medicines preemption generally fails where the manufacturer could have strengthened a warning independently through regulatory mechanisms.
Compounded versions raise separate issues. Products prepared by compounding pharmacies during shortages are not the approved medicine, may differ in formulation, and involve different defendants and different regulatory obligations.
What Patients Should Document
Pharmacy dispensing records identifying the specific product, manufacturer, dose and dates are essential, particularly to distinguish an approved medicine from a compounded preparation.
Medical records establishing diagnosis and timing matter most, including gastric emptying studies, imaging and hospital records. Prior gastrointestinal history is relevant because defendants will explore alternative causes.
Do not stop a prescribed medicine to support a claim
These medicines treat diabetes and other conditions with serious consequences if untreated. Any change belongs to you and your prescriber. Pursuing a claim never requires interrupting treatment, and doing so can be dangerous.
Before You Act
Thinking About Filing a Claim?
Most plaintiff lawyers offer a free initial consultation and work on contingency, meaning no fee unless there is a recovery. LawsuitWatch is not a law firm: we publish explainers, and we do not provide legal advice, representation or referrals. Your state bar directory is the reliable place to find and verify a lawyer.
GLP-1 Medication Lawsuits: Gastrointestinal Injury and Failure to Warn: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What do GLP-1 lawsuits allege?
That the medicines caused severe gastrointestinal conditions including gastroparesis and obstruction, and that warnings did not adequately convey the risk.
Why is slowed gastric emptying relevant?
It is part of how these medicines work, and the allegation concerns whether the severity and persistence of gastrointestinal outcomes was adequately conveyed.
Are compounded versions treated the same?
No. Compounded preparations are not the approved medicine, may differ in formulation, and involve different defendants and regulatory obligations.
What records are needed?
Pharmacy records identifying product, manufacturer, dose and dates, plus medical records including gastric emptying studies, imaging and hospital notes.
Should I stop taking the medication?
Not for legal reasons. These treat serious conditions, and any change should be made only with your prescriber. A claim never requires stopping treatment.
Legal Disclaimer
This article is general legal information, not legal advice, and does not create an attorney-client relationship. Case status, eligibility criteria, and any amounts described are as reported at the date shown and may change. Consult a licensed attorney in your jurisdiction about your own situation.